On February 2, 2022 AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, reported that Company management will participate in a fireside chat and one-on-one investor meetings during the SVB Leerink 11th Annual Global Healthcare Conference, taking place virtually February 14-18, 2022 (Press release, AC Immune, FEB 2, 2022, View Source [SID1234607637]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the fireside chat, Prof. Andrea Pfeifer, CEO, AC Immune SA, will discuss the Company’s corporate strategy and upcoming milestones including seven clinical readouts planned this year for both therapeutic and diagnostic candidates in development in neurodegenerative diseases, while highlighting its precision medicine approach.

The fireside chat will take place on February 16, 2022, at 8:00 am ET / 2:00 pm CET. A webcast of the fireside chat will be available on the Events Page of AC Immune’s website. Following the fireside chat, a replay will be archived in the same location.